Form 6-K RedHill Biopharma Ltd. For: Jan 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
RedHill Biopharma (RDHL) Completes pre-IND Meeting for RHB-104 Phase III; Offers Progress Update
January 29, 2015 7:14 AM ESTRedHill Biopharma (Nasdaq: RDHL) provided an update on the progress with the ongoing RHB-104 Phase III development program for the treatment of Crohn's disease. The Company, together with Quest Diagnostics (NYSE: DGX), recently concluded a pre-submission meeting with the FDA regarding the development path of a commercial companion diagnostic test for the detection of Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease patients. Following the constructive FDA meeting, RedHill intends to initiate a study of approximately 40 Crohn's disease patients to assess the clinical utility of the companion... More
